ClinicalTrials.gg
CompletedNCT00832390Updated May 30, 2017Results posted

Study to Assess the Efficacy and Safety of Sitagliptin in Recently Diagnosed, Naive Type 2 Diabetics With Inadequate Glycemic Control on Diet and Exercise (0431-158)

A Phase 4 interventional study of sitagliptin phosphate in Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 30 Years to 78 Years. Per ClinicalTrials.gov, last updated 2017-05-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Feb 2007, registered Jan 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
30 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing sitagliptin in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. sitagliptin · Diabetes Mellitus.

Enrollment
37th of 58
29 · median 45
Started
2007
with 3 others
Phase 4
29 of 58
none open now
Registered
15th of 58
by date
Lead sponsor
3 of 58
Merck Sharp & Dohme LLC

Among the 58 studies testing sitagliptin in Diabetes Mellitus, this one is the 37th largest by enrollment, is one of 4 that started in 2007, is one of 29 in phase 4, and was the 15th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 58 studies testing sitagliptin in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 30 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 58 studies testing sitagliptin in Diabetes Mellitus as a file.
02

Study summary

After 24 weeks of treatment evaluate the efficacy and security.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
30 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Patients Being Treated With Metformin
  • Patients With Between 6.5 % And 12.0%.
  • Type 2 DM
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    1

    sitagliptin

    Drug: sitagliptin phosphate

Interventions

  • Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets

    Also known as: MK0431

06

What researchers measure

Primary outcomes

  1. Change From Baseline in A1C at Week 24

    Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.

    Time frame: Baseline and 24 Weeks

07

Results

Posted Jul 31, 2009
Limitations and caveats
Few participants were recruited into this single-site study as the investigator preferred the use of initial combination therapy. Protocol deviations may have occurred that resulted in quality issues associated with reporting of the data.

Participant flow

Single site study with patients recruited in Principal Investigator's private practice, Mexico City. First Patient In: 14Feb2007. Last Patient's Last Visit: 11Jul2008

Participant flow — Overall Study
MilestoneSitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care Regimen
Started12161
Completed12161
Not completed000

Outcome measures

PrimaryChange From Baseline in A1C at Week 24

Week 24 A1C minus baseline (Week 0) A1C. The unit for A1C is "percent". Thus, this measure represents a difference of percent values.

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · Percent Difference
Change From Baseline in A1C at Week 24
Percent DifferenceSitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care Regimen
Change From Baseline in A1C at Week 24-0.2 (-0.9 to 0.5)-1.0 (-2.1 to -0.1)0.0 (0.0 to 0.0)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin 100 mg q.d. (Once Daily)—0/12 (0%)1/12 (8.3%)
Sitagliptin 100 mg q.d. (Once Daily) and Metformin—0/16 (0%)0/16 (0%)
Standard Care Regimen—0/1 (0%)0/1 (0%)
Most frequent other events
Most frequent other events
EventSitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care Regimen
HypertensionVascular disorders1/120/160/1

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care RegimenTotal
Mean57.6 ± 14.152.5 ± 9.351.0 ± 0.054.62 ± 11.43
Sex: Female, Male
Sex: Female, Male(Participants)Sitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care RegimenTotal
Female613120
Male6309
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Sitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care RegimenTotal
Mean27.4 ± 10.028.9 ± 5.226.0 ± 0.028.14 ± 7.41
Glycosylated Hemoglobin A1C (A1C)
Glycosylated Hemoglobin A1C (A1C)(Percent)Sitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care RegimenTotal
Mean7.1 ± 0.68.6 ± 1.46.9 ± 0.07.96 ± 1.33
Time Since Diagnosis of Diabetes
Time Since Diagnosis of Diabetes(Years)Sitagliptin 100 mg q.d. (Once Daily)Sitagliptin 100 mg q.d. (Once Daily) and MetforminStandard Care RegimenTotal
Mean5.3 ± 7.06.2 ± 6.05.2 ± 0.05.82 ± 6.25
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2007 to primary completion in Jul 2008, 16 months.

Results were first posted in Jul 2009, 1 year after primary completion.

Of 48 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 22. This study's 16 months is close to that.

Counting every sponsor, half of 197 studies reached it within 24 months; a quarter within 13 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2009
First posted
Jan 30, 2009
StartActual
Feb 14, 2007
Primary completionActual
Jul 11, 2008
CompletionActual
Jul 11, 2008
Results first posted
Jul 31, 2009
Last update
May 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00832390
Responsible party
Sponsor
First posted
Jan 30, 2009
Start date
Feb 14, 2007
Primary completion
Jul 11, 2008
Completion
Jul 11, 2008
Results posted
Jul 31, 2009
Last update
May 30, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion